Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | NDAQ

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Evolus, Inc. Develops neurotoxins and dermal fillers for the medical aesthetics market.	United States of America	EOLS
EXACT SCIENCES CORP Provides advanced cancer screening and diagnostic tests for early detection and treatment guidance.	United States of America	EXAS
EXELIXIS, INC. An oncology-focused biotech that discovers and develops medicines for hard-to-treat cancers.	United States of America	EXEL
EXICURE, INC. Develops nucleic acid therapies via its SNA™ platform for neurology, oncology, & genetic diseases.	United States of America	XCUR
ExpreS2ion Biotech Holding AB Clinical-stage biotech developing vaccines and immunotherapies via a proprietary protein platform.	Sweden	EXPRS2
EyeGene,Inc Develops gene/cell therapies & mRNA vaccines for age-related and ocular diseases.	South Korea	185490
EyePoint Pharmaceuticals, Inc. Develops innovative, sustained-delivery therapeutics for retinal diseases.	United States of America	EYPT
Faes Farma S.A. Develops and markets pharmaceuticals, like antihistamines, and animal nutrition products globally.	Spain	FAE
Fagron N.V. Supplies compounding ingredients and solutions for personalized medicine to healthcare professionals.	Belgium	FAGR
Farmak A pharmaceutical manufacturer and exporter of 400+ medicines to over 50 countries.	Ukraine	FARM